Kim Theilgaard-Mønch
Clinical Associate Professor, Research Director, Group leader
Department of Clinical Medicine
Blegdamsvej 9, 2100 KÃÂÃÂÃÂøbenhavn ÃÂÃÂÃÂÃÂ
Theilgaard Group
Ole Maaløes Vej 5
2200 København N.
Member of:
Education
1984 Graduation, Kurfürst-Friedrich Gymnasium, Heidelberg, DE.
1992 MD degree, Univ. Heidelberg, Munich, Hannover, DE.
1994 MD degree USA, ECFMG certificate.
2007 DMSc, Rigshospitalet, Univ. of CPH, DK.
2017 Board certified specialist Internal Medicine & Hematology, DK+SE.
Career
Since 2018
Combined clinical and research position: Senior Consultant, Dept. pf Hematology, Rigshospitalet, Group Leader and Associate Prof., Finsen Laboratory, Rigshospitalet, Biotech Research and Innovation Centre, Program for Translational Hematology, DanStem, NNF Center for Stem Cell Research Univ. of CPH, DK.
2008-2017
Combined clinical and research position: Since 2013 50% Group Leader and Associate Prof., Finsen Laboratory, Rigshospitalet & Biotech Research and Innovation Centre, Univ. of CPH, DK (Novo Nordisk clinical research scholarship 2013-2017), 50% Clinician, Dept. of Hematology, Univ. of Lund, SE.
2005-2007
Post.doc., Laboratory for Gene Therapy Research, Rigshospitalet, University of Copenhagen, Denmark.
1998-2004
DMSc research fellow, The Granulocyte Research Laboratory, Dept. of Hematology, Rigshospitalet, University of Copenhagen.
1992 -1998
Clinician, Dept. of Hematology-Oncology (24 month), University of Heidelberg, DE. Dept. of Clinical Immunology (21 month) and Dept. of Hematology (12 month), Rigshospitalet, University of CPH, DK.
Education
MD, DMSc, Associate Professor
ID: 3997971
Most downloads
-
2461
downloads
HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis
Research output: Contribution to journal › Journal article › peer-review
Published -
79
downloads
Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML
Research output: Contribution to journal › Journal article › peer-review
Published -
36
downloads
Phosphorylation of SHP2 at Tyr62 enables acquired resistance to SHP2 allosteric inhibitors in FLT3-ITD-driven AML
Research output: Contribution to journal › Journal article › peer-review
Published